Protagonist Therapeutics/$PTGX
1D1W1MYTD1Y5YMAX
Capital at risk
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
- Ticker
- $PTGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 141
- Headquarters
- Newark, United States
- Website
- www.protagonist-inc.com
PTGX Metrics
BasicAdvanced
$9.3B
117.10
$1.22
1.79
-
Price and volume
Market cap
$9.3B
Beta
1.79
52-week high
$160.81
52-week low
$61.64
Average daily volume
546K
Financial strength
Current ratio
21.709
Quick ratio
21.576
Long term debt to equity
0.008
Total debt to equity
0.011
Profitability
EBITDA (TTM)
59.883
Gross margin (TTM)
100.00%
Net profit margin (TTM)
29.40%
Operating margin (TTM)
20.69%
Effective tax rate (TTM)
1.69%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
4.55%
Return on equity (TTM)
10.98%
Valuation
Price to earnings (TTM)
117.098
Price to revenue (TTM)
32.815
Price to book
10.99
Price to tangible book (TTM)
10.99
Price to free cash flow (TTM)
70.865
Free cash flow yield (TTM)
1.41%
Free cash flow per share (TTM)
2.018
Growth
Revenue change (TTM)
34.81%
Earnings per share change (TTM)
51.80%
3-year earnings per share growth (CAGR)
-23.00%
10-year earnings per share growth (CAGR)
-35.13%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
Analyst projections of the future price of Protagonist Therapeutics stock.
Bulls say / Bears say
FDA accepted the New Drug Application for rusfertide and granted Priority Review with an August 2026 PDUFA date, positioning it for potential first-in-class approval in polycythemia vera (SEC).
Protagonist delivered Q2 2026 net income of $162.8 million, or $2.29 diluted EPS, compared to a net loss of $34.8 million in Q2 2025, reflecting a strong financial turnaround (SEC).
The FDA approval of ICOTYDE triggered a $50 million milestone payment in Q1 2026 and marks the first full quarter of commercial sales, with Protagonist eligible for up to $580 million in additional milestones and tiered royalties (SEC).
License and collaboration revenue of $213.5 million in Q2 2026 was driven primarily by a one-time $200 million opt-out payment from Takeda, raising concerns about the sustainability of Protagonist’s revenue stream (SEC).
Research and development expenses are expected to increase significantly in H2 2026 due to advancement of PN-881, PN-477, PN-458 and PN-8047 programs, which may accelerate cash burn and necessitate additional funding (SEC).
Protagonist’s decision to opt out of rusfertide development ceded worldwide commercialization rights to Takeda, limiting Protagonist’s control and upside beyond upfront and milestone payments (SEC).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
Upcoming events
No upcoming events
PTGX News
AllArticlesVideos
Funds containing PTGX
AllEURUSDGBP
Fund name | Fund size | $PTGX weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.64% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.61% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.61% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.50% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.50% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.